LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development
YQ Gong,RB Slee,N Fukai,G Rawadi,S Roman-Roman,AM Reginato,HW Wang,T Cundy,FH Glorieux,D Lev,M Zacharin,K Oexle,J Marcelino,W Suwairi,S Heeger,G Sabatakos,S Apte,WN Adkins,J Allgrove,M Arslan-Kirchner,JA Batch,P Beighton,GCM Black,RG Boles,LM Boon,C Borrone,HG Brunner,GF Carle,B Dallapiccola,A De Paepe,B Floege,ML Halfhide,B Hall,RC Hennekam,T Hirose,A Jans,H Juppner,CA Kim,K Keppler-Noreuil,A Kohlschuetter,D LaCombe,M Lambert,E Lemyre,T Letteboer,L Peltonen,RS Ramesar,M Romanengo,H Somer,E Steichen-Gersdorf,B Steinmann,B Sullivan,A Superti-Furga,W Swoboda,MJ van den Boogaard,W Van Hul,M Vikkula,M Votruba,B Zabel,T Garcia,R Baron,BR Olsen,ML Warman
DOI: https://doi.org/10.1016/s0092-8674(01)00571-2
IF: 64.5
2001-01-01
Cell
Abstract:In humans, low peak bone mass is a significant risk factor for osteoporosis. We report that LRP5, encoding the low-density lipoprotein receptor-related protein 5, affects bone mass accrual during growth. Mutations in LRP5 cause the autosomal recessive disorder osteoporosis-pseudoglioma syndrome (OPPG). We find that OPPG carriers have reduced bone mass when compared to age- and gender-matched controls. We demonstrate LRP5 expression by osteoblasts in situ and show that LRP5 can transduce Wnt signaling in vitro via the canonical pathway. We further show that a mutant-secreted form of LRP5 can reduce bone thickness in mouse calvarial explant cultures. These data indicate that Wnt-mediated signaling via LRP5 affects bone accrual during growth and is important for the establishment of peak bone mass.